Physician

Andrew Brohl, M.D.

According to 2025 Medicare claims, Andrew Brohl, M.D. (NPI: 1609022870) practices medical oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is H LEE MOFFITT CANCER CTR & RES INST LIFE TIME CANCER SCRN CTR INC (NPI: 1306833595; TIN: 593238640) and primary practice location at 33612-9416.

Brohl's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 120 traditional Medicare patients, billed 221 HCPCS/CPT codes, and received $19,989 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 207 prescription claims across 52 beneficiaries totaling $922,118 in drug costs, led by Gleevec (Imatinib Mesylate). 2022 DME data shows 48 claims. Open Payments data shows 20 records totaling $1,883,008. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $116,285 to $922,118. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	52	116	$10,299
2016	83	196	$15,403
2017	157	384	$32,891
2018	189	451	$38,225
2019	178	416	$36,328
2020	162	318	$28,028
2021	141	255	$23,311
2022	121	196	$20,636
2023	120	207	$21,270
2024	120	221	$19,989

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	21	47	$116,285
2016	27	102	$358,052
2017	60	249	$689,622
2018	78	355	$622,701
2019	82	378	$880,736
2020	76	406	$1,446,727
2021	65	292	$1,007,443
2022	64	249	$951,061
2023	53	202	$770,071
2024	52	207	$922,118

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	11	$133
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	48	$34,543
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	31	31	$144
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	40	53	$114
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	61	83	$76
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	11	13	$50
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	16	20	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Gleevec	Imatinib Mesylate	12	420	$153,259
Pazopanib Hcl	Pazopanib Hcl	18	540	$152,885
Imatinib Mesylate	Imatinib Mesylate	18	540	$28,192
Levothyroxine Sodium	Levothyroxine Sodium	20	1,200	$146
Pantoprazole Sodium	Pantoprazole Sodium	14	600	$110

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$4,297	Deciphera Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	13	$1,878,711	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Brohl, M.D.?

Tedicare shows public-source Medicare data for Andrew Brohl, M.D. (NPI 1609022870), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Brohl, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew Brohl, M.D.?

Andrew Brohl, M.D. is linked to H LEE MOFFITT CANCER CTR & RES INST LIFE TIME CANCER SCRN CTR INC (billing NPI 1306833595) in the available physician profile data.

Does Andrew Brohl, M.D. have Open Payments data?

Andrew Brohl, M.D. has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.